ReviewCritical reviews in immunology2013
Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy.
Review in Critical reviews in immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 44 citations in OpenAlex.
- Musculoskeletal abscopal effect: a review of the important imaging findings and their clinical relevance.Skeletal radiology · 2025Review
- CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model.Experimental hematology & oncology · 2022Article
- Beyond Immunosuppression: The Multifaceted Functions of Tumor-Promoting Myeloid Cells in Breast Cancers.Frontiers in immunology · 2022Review
- Murine precursors to type 1 conventional dendritic cells induce tumor cytotoxicity and exhibit activated PD-1/PD-L1 pathway.PloS one · 2022Article
- The Immune Privilege of Cancer Stem Cells: A Key to Understanding Tumor Immune Escape and Therapy Failure.Cells · 2021Review
- Effective Cytotoxicity of Dendritic Cells against Established T Cell Lymphomas in Mice.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Review
- Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.Theranostics · 2020Article
- The Cross Talk between Cancer Stem Cells/Cancer Initiating Cells and Tumor Microenvironment: The Missing Piece of the Puzzle for the Efficient Targeting of these Cells with Immunotherapy.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2019Article
- Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.Journal of experimental & clinical cancer research : CR · 2019Article
- Article
- Cancer stem cells as targets for DC-based immunotherapy of colorectal cancer.Scientific reports · 2018Article
- Skin Allografting Activates Anti-tumor Immunity and Suppresses Growth of Colon Cancer in Mice.Translational oncology · 2018Article
- Anticancer Mechanisms in Two Murine Bone Marrow-Derived Dendritic Cell Subsets Activated with TLR4 Agonists.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- Docosahexaenoic acid (DHA) promotes immunogenic apoptosis in human multiple myeloma cells, induces autophagy and inhibits STAT3 in both tumor and dendritic cells.Genes & cancer · 2017Article
- The emerging roles of exosomes in leukemogeneis.Oncotarget · 2016Review
- Capsaicin triggers immunogenic PEL cell death, stimulates DCs and reverts PEL-induced immune suppression.Oncotarget · 2015Article
- Modeling putative therapeutic implications of exosome exchange between tumor and immune cells.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- PIAS1 and STAT-3 impair the tumoricidal potential of IFN-γ-stimulated mouse dendritic cells generated with IL-15.European journal of immunology · 2014Article
- HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV-positive tumour cells.Journal of cellular and molecular medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Universally viewed as the sentinels and messengers of the immune system and traditionally referred to as professional antigen-presenting cells, dendritic cells (DCs) play a fundamental role in antitumor immunity. DCs are uniquely equipped with the ability to acquire, process, and present to T lymphocytes tumor-derived antigens. They can drive the differentiation of naive T cells into activated tumor-specific effector lymphocytes. DCs also dictate the type and regulate the strength and duration of T-cell responses. In addition, they contribute to natural killer and natural killer T-cell antitumoral function and to B-cell-mediated immunity. Besides this cardinal role as orchestrators of innate and adaptive immune responses, many studies have provided evidence that DCs can also function as direct cytotoxic effectors against tumors. This less conventional aspect of DC function has, however, raised controversy as it relates to the origin of these cells and the induction, regulation, and mechanisms underlying their tumoricidal activity. The possible impact of the cytotoxic function of DCs on their capability to present antigens also has been the focus of intensive research. This review examines these questions and discusses the biological significance of this nontraditional property and possible strategies to exploit the killing potential of DCs in cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.